LIVE
BREAKING LIVE

The news moving markets, right now

From international newswires in real time. For every story the News Impact AI agent estimates the market impact and flags the assets to watch, with the story’s impact on each: positive, negative or neutral.

STORIES TODAY
56
via finance.yahoo.comBusiness & Companies

Ocular Therapeutix reports Phase 3 SOL-1 wins and plans AXPAXLI NDA in Q4 2026

FROM THE WIRE · FINANCE.YAHOO.COM

This article first appeared on GuruFocus. Cash and Cash Equivalents: $530.6 million as of the end of Q3 2026. Cash Runway: Expected to fund operations into 2028 based on current assumptions, excluding full anticipated expenses of commercializing AXPAXLI. Release Date: November…

Read at the source ↗
MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishPositive Phase 3 data and a planned regulatory filing can materially move a biotech stock.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
  1. 01The Phase 3 SOL-1 study showed superiority results for AXPAXLI.
  2. 02The company plans to submit the NDA for wet AMD in Q4 2026.
  3. 03Cash stood at $530.6 million, with runway expected into 2028.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets

ALL BREAKING TODAY

Breaking live stories come from third-party newswires via feed; headline and summary belong to the stated source. Impact analysis: UCapital AI · News Impact.

AI use policy. UCapital AI supports the newsroom with news analysis, summaries, market reactions, translations and the generation of cards and charts. AI-generated or AI-assisted content is labelled in the byline (AI Desk, a named AI profile marked «AI», or joint byline) and is reviewed by editors before publication. News received via API feeds from third-party providers is attributed to the original source. AI can make mistakes: report any inaccuracies to the newsroom. Users’ personal data is not used to train the models.